From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

[1]  Akane Kawamura,et al.  Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells , 2017, Cell chemical biology.

[2]  Jun Liang,et al.  Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[3]  P. Trojer,et al.  Identification of potent, selective KDM5 inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[4]  Jun Liang,et al.  Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. , 2016, Bioorganic & medicinal chemistry letters.

[5]  M. Chandrasekar,et al.  Inhibitors of histone deacetylase as antitumor agents: A critical review. , 2016, Bioorganic chemistry.

[6]  Margaret A. Johns,et al.  Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. , 2016, Cell chemical biology.

[7]  P. Trojer,et al.  An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. , 2016, Nature chemical biology.

[8]  R. Prinjha,et al.  Structural analysis of human KDM5B guides histone demethylase inhibitor development. , 2016, Nature chemical biology.

[9]  Akane Kawamura,et al.  Recent Progress in Histone Demethylase Inhibitors. , 2016, Journal of medicinal chemistry.

[10]  Douglas W. Thomson,et al.  Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives. , 2016, Journal of medicinal chemistry.

[11]  David M. Wilson,et al.  Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives. , 2016, Journal of medicinal chemistry.

[12]  G. F. Ruda,et al.  8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors , 2016, Journal of medicinal chemistry.

[13]  Kristian Helin,et al.  Histone lysine demethylases as targets for anticancer therapy , 2013, Nature Reviews Drug Discovery.

[14]  P. Gimotty,et al.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[15]  Yukihiro Itoh,et al.  Small-molecular modulators of cancer-associated epigenetic mechanisms. , 2013, Molecular bioSystems.

[16]  J. Whetstine,et al.  Histone lysine methylation dynamics: establishment, regulation, and biological impact. , 2012, Molecular cell.

[17]  Kristian Helin,et al.  Molecular mechanisms and potential functions of histone demethylases , 2012, Nature Reviews Molecular Cell Biology.

[18]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[19]  S. Yokoyama,et al.  Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. , 2011, Genes & development.

[20]  Takayoshi Suzuki,et al.  Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.

[21]  K. Helin,et al.  Inhibitors of histone demethylases. , 2011, Bioorganic & medicinal chemistry.

[22]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[23]  D. Reinberg,et al.  Chromatin structure and the inheritance of epigenetic information , 2010, Nature Reviews Genetics.

[24]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[25]  Juri Rappsilber,et al.  The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3 , 2006, Nature.

[26]  Nicola Mongelli,et al.  Rapid NMR‐based functional screening and IC50 measurements performed at unprecedentedly low enzyme concentration , 2005 .

[27]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[28]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.